Avalglucosidase alfa Drug Aliquot | Anti Lysosomal glycogen | Therapeutic Enzyme

Aliquoted from the original reference drug | Now available for research use

Aliquots of the original Avalglucosidase alfa are now available as research consumables.

Avalglucosidase alfa drug aliquots can be used for in vitro or in vivo experiments. Several other reference drugs are also available.

The drug aliquots are generated by aliquoting (dividing and repackaging) the EU-licensed reference drug.

Not looking for Avalglucosidase alfa Reference Drug?

Search our therapeutic molecules product database

Quick Ordering

Find and order your therapeutic molecules through smart filters

Multiple Batches

Up to 10 batches of original drugs for examining batch-to-batch variations

Reduce Costs

Up to 80% less compared to the original pharmaceutical price

Worldwide Shipping

Shipment within days worldwide according to GDP-standards

Precise Quantity​​

Up to 80% less compared to the original pharmaceutical price

Nexviadyme® / Avalglucosidase alfa Reference Product

Drug nameNexviadyme®
INNAvalglucosidase alfa
API typeEnzyme
Pharmacotherapeutic group
Not assigned yet
ATC code
Not assigned yet
Target of antibody
Lysosomal glycogen
General function
Short descriptionAvalglucosidase alfa is indicated for long-term enzyme replacement therapy for the treatment of patients with Pompe disease (acid α-glucosidase deficiency).
Pharmacodynamic properties
(Mechanism of action; Source EMA document)
Avalglucosidase alfa is a recombinant human acid α-glucosidase (rhGAA) that provides an exogenous source of GAA. Avalglucosidase alfa is a modification of alglucosidase alfa in which approximately 7 hexamannose structures each containing 2 terminal mannose-6-phosphate (bis-M6P) moieties are conjugated to oxidized sialic acid residues on alglucosidase alfa. Avalglucosidase alfa has a 15-fold increase in mannose-6-phosphate (M6P) moieties compared with alglucosidase alfa. Binding to M6P receptors on the cell surface has been shown to occur via carbohydrate groups on the GAA molecule, after which it is internalised and transported into lysosomes, where it undergoes proteolytic cleavage that results in increased enzymatic activity to degrade glycogen.
Pharmacodynamic properties (Pharmacodynamic effects; Source EMA document)Avalglucosidase alfa is a recombinant alpha-glucosidase (GAA) enzyme that catalyzes hydrolysis of glycogen. In clinical trials, avalglucosidase alfa reduced the levels of glycogen excreted in the urine of patients with Pompe disease, indicating that it effectively cleaved excess glycogen. Avalglucosidase alfa has significantly higher binding affinity for cation-independent mannose-6-phosphate receptor (CI-MPR) for cellular uptake and better muscle targeting than alglucosidase alfa. In GAA-deficient mice, avalglucosidase alfa reduced glycogen with more efficacy than alglucosidase alfa at an equivalent dose.
Original license holder
Sanofi B.V.
Paasheuvelweg 25
1105 BP Amsterdam
The Netherlands
Marketing authorisation numbers
Marketing authorisation holder
Sanofi B.V.
Paasheuvelweg 25
1105 BP Amsterdam
The Netherlands
Name of the manufacturer of the biological active substance
Genzyme Flanders
Cipalstraat 8
2440 Geel, Belgium
Name and address of the manufacturer(s) responsible for batch releaseGenzyme Ireland Limited,
IDA Industrial Park,
Old Kilmeaden Road,
Waterford, Ireland
Max shelf life
4 years
Storage conditions
2°C – 8°C
List of excipients
Histidine hydrochloride monohydrate
Polysorbate 80

Evidentic – fast, accurate, secure

Our products are empowering researchers worldwide​

Evidentic offers multiple batches of original drug aliquots in low binding Eppendorf tubes for research use only. We provide licence-free drug aliquots with long, short or even “negative shelf life” by storing the products at recommended temperatures (either 2-8°C or -80°C) and ensuring fully functional molecules for research purposes.